**Proteins** 



## **EWP 815**

Cat. No.: HY-148001 CAS No.: 20231-01-0 Molecular Formula:  $C_{12}H_{22}N_4S_4$ Molecular Weight: 350.59

Target: Phosphatase; Dopamine  $\beta$ -hydroxylase

Pathway: Metabolic Enzyme/Protease Storage: 4°C, protect from light

\* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 50 mg/mL (142.62 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.8523 mL	14.2617 mL	28.5233 mL
	5 mM	0.5705 mL	2.8523 mL	5.7047 mL
	10 mM	0.2852 mL	1.4262 mL	2.8523 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.25 mg/mL (3.57 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.25 mg/mL (3.57 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	EWP 815 is a disulfiram analogue, is a potent inhibitor of $Ins(1,4)P_2$ phosphatase and $Ins(1,4,5)P_3$ 5-phosphatase. EWP 815 also inhibits enzyme dopamine $\beta$ -hydroxylase activity <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	$Ins(1,4)P2\ phosphatase; Ins(1,4,5)P3\ 5-phosphatase^{[1]}; dopamine\ \beta-hydroxylase^{[2]}$
In Vitro	EWP 815 inhibits thyrotropin-releasing hormone (TRH; 0.03 mM)-stimulated inositol phospholipid breakdown without affecting basal breakdown rates in prelabelled $GH_3$ cells with $IC_{50}$ s of 83 mM (soluble enzymes) and 71 mM (particulate enzymes), respectively <sup>[1]</sup> . EWP 815 (30 $\mu$ M; 1 h) exerts higher inhibition on $Ins(1,4)P_2$ phosphatase rather than $Ins(1,4,5)P_3$ 5-phosphatase with the mean $[^3H]Ins(1,4)P_2/mean [^3H]InsP$ recovery ratio of $2.6^{[1]}$ . EWP 815 (6, 8 $\mu$ M; 10 min) inhibits dephosphorylation of $[^3H]Ins(1,4,5)P_3$ 5-phosphatase in particulate and soluble fractions

	EWP 815 (3-300 μM; 30 production by 30% (100	with IC $_{50}$ s of 6 $\mu$ M and 8 $\mu$ M, respectively <sup>[1]</sup> . EWP 815 (3-300 $\mu$ M; 30 min) suppresses thyrotropin-releasing hormone (TRH)-stimulated (100 nM) inositol phospholipid production by 30% (100 $\mu$ M) and 1.8% (300 $\mu$ M), respectively, without affecting Ins(1,4,5)P $_3$ binding <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo		EWP 815 (50 mg/kg; i.p.; 30 min before killed) inhibits the enzyme dopamine β-hydroxylase activity in mice <sup>[2]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.  Animal Model: Female mice (20 g) <sup>[2]</sup>		
	Dosage:	50 mg/kg		
	Administration:	Intraperitoneal injection; 30 min before killed		
	Result:	Intraperitoneal injection; 30 min before killedInhibited $\beta$ -hydroxylase of $^3$ H- $\alpha$ -methyldopamine. Reduced the amount of $^3$ H- $\alpha$ -Me-NA by 12%.		

## **REFERENCES**

[1]. Fowler CJ, et al. Inhibition of inositol 1,4,5-trisphosphate 5-phosphatase by micromolar concentrations of disulfiram and its analogues. Biochem J. 1993 Feb 1;289 (Pt 3)(Pt 3):853-9.

[2]. Carlsson A, et al. On the beta-hydroxylation of (+-)-alpha-methyldopamine in vivo. Eur J Pharmacol. 1968 Dec;5(1):85-92.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA